AS_Hero_Contact

News & Insights

Joshua Lowitz

Joshua Lowitz

Josh is the Manager of Project Management of Antibody Solutions. Since joining the company in 2010, Josh has served multiple roles at the company and is currently providing scientific support and guidance to the Project Management team as well as helping clients achieve their antibody discovery and research needs.

Recent posts by Joshua Lowitz

6 min read

Functional Assays: Narrowing the Field from Binders to Therapeutic Candidates

By Joshua Lowitz on 06/28/2021

Candidate ID: How to go from hits to lead candidates

We tend to think of antibodies as being defined by their specificity and affinity to a particular antigen. Of equal importance, however, are the functional activities of an antibody upon antigen binding. All are valuable to the discovery of therapeutic antibodies, where the goal is to have a drug that can react with a specific disease target and modify its role in the disease. We describe in this post the types of assays and strategies used to identify the most promising therapeutic antibody candidates.

Topics: antibody discovery Therapeutic Targets immunoassays Functional Assays
5 min read

Cell Fusion: A trusted tool that can still be an enigma

By Joshua Lowitz on 02/24/2021

“Mystery is at the heart of creativity. That, and surprise.”  Julia Cameron

Topics: Insights Hybridoma cell fusion
5 min read

Measure Twice, Cut Once: The Value of Target Analysis in Antibody Discovery

By Joshua Lowitz on 01/12/2021

Editor’s note: Welcome to 2021, and to our first in a year-long series of posts that will explore the essentials in antibody discovery. We’re starting off with a frequently under-appreciated technique for getting to “yes” or “no” faster — target analysis. Next up, in early February, we’ll be talking about fusions. Thanks for reading, and we invite your ideas on what you consider to be “the essentials” of antibody research success.

Topics: Insights Therapeutic Targets target analysis immunogens
4 min read

Expanding the Repertoire of Antibody Drug Discovery with Lambda Light-Chain Models

By Joshua Lowitz on 11/30/2020

Accessing the Untapped Potential of 33% of Human IgG

Topics: Transgenic Animals Lambda Mouse lambda light chain